T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Ultragenyx Pharmaceutical
RARE
$2.62B
| $123M | 0.01% |
2,991,958
-576,915
| -16% | -$24.6M |
|
502
IQVIA
IQV
$40.1B
| $123M | 0.01% |
579,823
-307,125
| -35% | -$69.8M |
|
503
Armstrong World Industries
AWI
$7.79B
| $123M | 0.01% |
1,082,521
-412,442
| -28% | -$47.8M |
|
504
Kimco Realty
KIM
$16.3B
| $122M | 0.01% |
6,289,456
+442,513
| +8% | +$8.29M |
|
505
Roblox
RBLX
$25.9B
| $122M | 0.01% |
3,285,808
-1,451,849
| -31% | -$51.7M |
|
506
New Oriental
EDU
$8.38B
| $122M | 0.01% |
1,569,360
+378,501
| +32% | +$30.8M |
|
507
Alamos Gold
AGI
$13.7B
| $122M | 0.01% |
7,754,677
+1,166,096
| +18% | +$18.3M |
|
508
Truist Financial
TFC
$65B
| $120M | 0.01% |
3,088,727
-400,684
| -11% | -$15.1M |
|
509
Agios Pharmaceuticals
AGIO
$2.02B
| $120M | 0.01% |
2,777,259
+764,266
| +38% | +$27.6M |
|
510
Curtiss-Wright
CW
$26.3B
| $119M | 0.01% |
440,376
+876
| +0.2% | +$234K |
|
511
On Holding
ONON
$10.2B
| $119M | 0.01% |
3,059,019
+271,148
| +10% | +$9.91M |
|
512
Global X US Infrastructure Development ETF
PAVE
$14.3B
| $118M | 0.01% |
+3,180,115
| New | +$122M |
|
513
Celldex Therapeutics
CLDX
$3.48B
| $117M | 0.01% |
3,172,399
+85,191
| +3% | +$3.21M |
|
514
International Flavors & Fragrances
IFF
$21.6B
| $117M | 0.01% |
1,233,115
-662,466
| -35% | -$60.7M |
|
515
Service Corp International
SCI
$11.5B
| $117M | 0.01% |
1,645,928
-1,815,185
| -52% | -$129M |
|
516
NetApp
NTAP
$40.9B
| $116M | 0.01% |
903,367
+509,392
| +129% | +$57.2M |
|
517
Murphy USA
MUSA
$10.1B
| $116M | 0.01% |
246,133
+913
| +0.4% | +$398K |
|
518
Fabrinet
FN
$20.9B
| $115M | 0.01% |
471,563
+15,777
| +3% | +$3.35M |
|
519
Agnico Eagle Mines
AEM
$91.1B
| $115M | 0.01% |
1,756,198
-131,863
| -7% | -$8.6M |
|
|
SRCL
520
DELISTED
Stericycle Inc
SRCL
| $115M | 0.01% |
1,971,515
-170,186
| -8% | -$8.74M |
|
521
Arthur J. Gallagher & Co
AJG
$65.4B
| $114M | 0.01% |
440,737
+5,162
| +1% | +$1.28M |
|
522
Biohaven
BHVN
$2.17B
| $114M | 0.01% |
3,284,479
-62,543
| -2% | -$2.47M |
|
523
TransUnion
TRU
$15.4B
| $113M | 0.01% |
1,525,296
-5,230,433
| -77% | -$390M |
|
524
Capital One
COF
$137B
| $113M | 0.01% |
815,413
-399,516
| -33% | -$56M |
|
525
MoonLake Immunotherapeutics
MLTX
$1.43B
| $113M | 0.01% |
2,561,512
+425,629
| +20% | +$18M |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.